Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
01672 ASCLETIS-B
RTNominal up1.430 +0.020 (+1.418%)
Others

10/11/2021 15:34

Ascletis (01672) gets clinical trial approval

[ET Net News Agency, 10 November 2021] Ascletis Pharma Inc. (01672) announced the
approval of the Phase II clinical trial of ASC22 (Envafolimab) by China National Medical
Products Administration (NMPA) for the proposed new indication of immune
restoration/functional cure of human immunodeficiency virus 1 (HIV-1) infected patients.
ASC22 (Envafolimab) is a subcutaneously administered single domain antibody against
PD-L1 and has the potential to restore virus-specific immune responses in patients with
chronic viral infection. Immune restoration/functional cure in HIV-1 infected patients is
the second indication of ASC22 developed by Ascletis, in addition to functional cure of
chronic hepatitis B (CHB) patients. (RC)

Remark: Real time quote last updated: 28/03/2024 18:00
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2024 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.